undamentalytics Newsletter
Sign in

Jupiter Neurosciences, Inc. (JUNS) stock

Add to watchlist

Add holding +

NASDAQ: JUNS Nasdaq Biotechnology

Jupiter Neurosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Jupiter Neurosciences, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Jupiter Neurosciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds7 adding, 7 cuttingOf 1 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 12% in the quarter to 2025-09-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Jupiter Neurosciences, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 121% and a beta of 1.6 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$5.25 against an average estimate of -$6.00: beat by 12.5%
Revenue
$0m

Jupiter Neurosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.6%
  • 1 week-7.6%
  • 1 month-4.3%
  • This year-97.0%
  • 1 year-97.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-21.68

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Governance
  2. Announcement
  3. Leadership
  4. Announcement
  5. Agreement
  6. Announcement
  7. Share issue
  8. Shareholder vote
  9. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Jupiter Neurosciences, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Jupiter Neurosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$0.1–$0.3 Left out: out of range vs price (0.02x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Jupiter Neurosciences, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025
Share price$802.50$76.50
Market value$23.1bn$2.6bn
+ Net debt (− = net cash)$0$0
Enterprise value$23.1bn$2.6bn
Multiples
Price / sales —n/m
Price / earnings ——
Price / free cash flow ——
EV / EBITDA ——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Jupiter Neurosciences, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2025 −$6.00 −$5.25 +12.5%
Jun 2025 −$5.25 −$5.25 0.0%
Mar 2025 −$2.25 −$3.75 −66.7%
Dec 2024 −$1.50 −$3.75 −150.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
3.4%
of tradable shares
Days to cover
0.44
at average volume
Short interest, 1 month
−26%
to October 15, 2026
Held by institutions
2%
of shares
Held by insiders
30.0%
of shares
Employees
5
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
JUNS−91%−97%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
JUNS50%27%
S&P 50075%46%
Largest fall from a high during the year
JUNS−95%−97%
S&P 500−19%−9%

Worst fall since December 3, 2024: 100% from December 12, 2024 to October 30, 2026. Getting back needed a 56132% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.05 – $103.50
From 52-week high
−97.8%
vs 50-day average
−25.2%
vs 200-day average
−88.6%
Volatility (1 year)
121%
Beta vs S&P 500
1.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0 22
Gross profit — 18
Operating income −3,091 −8,909
Net income −2,440 −8,645
Diluted EPS −$0.08 −$0.25
Margins
Gross margin — 80.6%
Operating margin — <−999%
Net margin — <−999%
Cash flow
Cash from operations −3,911 −5,414
Stock-based pay 1,841 2,419
Balance sheet
Total debt 649 5,298
Diluted shares 29m 35m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $4m
Short-term assets $3mLonger-term assets $1m
What it owes, and who funded it · $4m
Short-term liabilities $4mLonger-term liabilities $0mShareholders' equity $-0m
  • Short-term assets cover short-term liabilities $3m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $3m short-term assets against $205,068 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$10m against $272,918 of interest.

From Jupiter Neurosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Who owns it

Funds buying and selling
Reported value
$270,430
Institutions reporting
13
Shares held vs prior quarter
▼ 34.2%
Positions opened / closed
6 / 3

Top buyers and sellers, Q2 2026: 7 institutions bought and 7 sold ; the biggest buyer was Jane Street Group, LLC (+533K shares) and the biggest seller Vestor Capital, LLC (−969K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jane Street Group, LLC $114,253 533K 42.2% New
Virtu Financial LLC $50,000 231K 18.5% ▲ 1603.4%
Geode Capital Management, LLC $33,441 156K 12.4% ▼ 26.2%
Vanguard Capital Management LLC $27,401 128K 10.1% ▼ 64.4%
Vanguard Fiduciary Trust Co $18,013 84K 6.7% ▼ 4.1%
Xtx Topco Ltd $7,019 33K 2.6% New
Tower Research Capital LLC (TRC) $6,166 29K 2.3% New
Stonex Group Inc. $5,678 21K 2.1% New
Northern Trust Corp $5,429 25K 2.0% 0.0%
Level Four Advisory Services, LLC $2,142 10K 0.8% New
Vestor Capital, LLC $557 2K 0.2% ▼ 99.8%
Midfirst Bank $214 1K 0.1% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Jupiter Neurosciences, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Jupiter Neurosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Jupiter Neurosciences, Inc. in brief

What does Jupiter Neurosciences, Inc. do?
Jupiter Neurosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Jupiter Neurosciences, Inc.'s stock ticker?
Jupiter Neurosciences, Inc. trades under the ticker JUNS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Jupiter Neurosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jane Street Group, LLC, Virtu Financial LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Jupiter Neurosciences, Inc.'s market cap?
On December 31, 2025, Jupiter Neurosciences, Inc.'s market capitalisation was about $2.6B and net debt of $0. Market figures come from third-party market data and may be delayed.